PHARMACOLOGICAL COMPOSITION FOR TREATMENT OF GALLBLADDER CARCINOMA WHICH TARGETS METALLOPROTEINASE-19 IN N-MYC DOWNSTREAM-REGULATED GENE 2 DEPLETED GALLBLADDER CARCINOMA PATIENT, METHOD FOR SUPPRESSING GROWTH AND TRANSFERENCE OF GALLBLADDER CARCINOMA USING SAME, AND TREATMENT METHOD

摘要

The present invention confirmed that a gallbladder carcinoma cell having the loss of N-myc downstream-regulated gene 2 (NDRG2) expression increases cellular multiplication, cellular transference, and cellular infiltration and the loss of the NDRG2 expression induces the expression of matrix metalloproteinase-19 (MMP-19) and the increased MMP-19 increase the expression of Slug and the Slug induces the expression of tyrosine-kinase Axl which is an acceptor to promote epithelial-mesenchymal transition of the gallbladder carcinoma cell as the investigation result of a functional role of the NDRG2 and an underlying molecular mechanism of disease progression in gallbladder carcinoma. Therefore, the expression of MMP-19 protein and NDRG2 protein or an active inhibitor can be usefully used as an active ingredient of a pharmacological composition for cancer treatment or transference inhibition.;COPYRIGHT KIPO 2016